Company news
Rebus Hldgs Inc. (OTC:RBSH) news
Rebus Hldgs Inc. news releases on 6ix. Latest, Oct 23, 2017: Inspyr Therapeutics Announces Research Collaboration with the National Institutes of Health
Press releases & updates
Inspyr Therapeutics Announces Research Collaboration with the National Institutes of Health
October 23, 2017
Inspyr Therapeutics Announces Research Collaboration with NYU Winthrop Hospital
October 4, 2017
Inspyr Therapeutics Announces Research Collaboration with University of Virginia School of Medicine
October 2, 2017
Inspyr Therapeutics and Lewis and Clark Pharmaceuticals Complete Merger
September 13, 2017
Inspyr Therapeutics Announces Private Placement of Senior Convertible Debentures
September 12, 2017
Inspyr Therapeutics and Lewis and Clark Pharmaceuticals to Merge
May 30, 2017
Inspyr Therapeutics Signs Commitment Letter with Milost Global
March 28, 2017
Inspyr Therapeutics Secures a $100 Million Financing Agreement from Milost Global
March 17, 2017
Inspyr Therapeutics Appoints NIH Veterans to Lead New Translational Medicine Initiatives and Pipeline Expansion
March 6, 2017
Inspyr Therapeutics Initiates Mipsagargin Combination Therapy Program for Gastric Cancer
February 22, 2017
Inspyr Therapeutics Initiates Mipsagargin with Nexavar® Combination Therapy Programs for Liver Cancer
January 3, 2017
UPDATE -- Inspyr Announces Private Placement of $1.0 Million
December 12, 2016
Inspyr Broadens Intellectual Property Portfolio with New Patent Issued on Methods for Producing Cancer Compounds
October 20, 2016
Inspyr Therapeutics Appoints Richard Buller, M.D., Ph.D. to Board of Directors
October 13, 2016
Inspyr Therapeutics Appoints Claire Thom, Pharm.D. to Board of Directors
October 12, 2016
Inspyr Therapeutics Strengthens Clinical Development Capabilities with Appointment of Michael Elliott as Vice President of Clinical Operations
October 11, 2016
Phyton Biotech Achieves Manufacturing Milestone with Thapsigargin, the Active Agent in Mipsagargin
August 22, 2016
Inspyr Therapeutics Announces the Initiation of a Phase 2 Clinical Trial of Mipsagargin for Newly Diagnosed Prostate Cancer Patients
August 17, 2016
Inspyr Therapeutics Appoints Ronald Shazer, M.D., as Senior Vice President and Chief Medical Officer
August 8, 2016
Inspyr Therapeutics Appoints Christopher Lowe Chief Executive Officer and Director
August 4, 2016
GenSpera Announces Name Change to Inspyr Therapeutics
August 1, 2016
GenSpera Announces Management Changes
March 22, 2016
GenSpera Engages FLG Partners LLC and Partner Chris Lowe for Strategic Business Advisory Services
March 11, 2016
GenSpera Issues Letter to Stockholders
January 6, 2016
GenSpera Announces Private Placement of $2.5 Million
December 23, 2015
GenSpera to Present at ICV Manhattan Investor Conference
December 8, 2015
Mipsagargin Demonstrates Clinical Benefit in Subset of Glioblastoma Patients
November 20, 2015
GenSpera Provides Update on Clinical Development Programs
November 13, 2015
World-Renowned Neuro-Oncologist Santosh Kesari, MD, PhD Joins GenSpera’s Scientific Advisory Board
October 29, 2015
GenSpera to Present at the BIO Investor Forum
October 14, 2015
GenSpera Announces Encouraging Interim Phase II Data for Glioblastoma, Showcases Positive Future for Mipsagargin Across Multiple Types of Solid Tumors
September 9, 2015
GenSpera to Present at Rodman & Renshaw 17th Annual Global Investment Conference
August 24, 2015
GenSpera Provides 2nd Quarter Corporate Update
August 10, 2015
GenSpera Phase II Abstract Accepted for Presentation at the Society of Neuro-Oncology 20th Annual Scientific Meeting
July 28, 2015
U.S. Court of Appeals Enters Judgment in Favor of GenSpera
July 20, 2015
Patent Application for GenSpera Partner Phyton Biotech Is Published by World Intellectual Property Organization (WIPO)
July 15, 2015
U.S. Food and Drug Administration's Office of Orphan Products Development Issues Grant Supporting GenSperas Glioblastoma Study
June 17, 2015
Craig A. Dionne to Speak at BIO International 2015
June 15, 2015
KTLA TV's Health Smart Showcases GenSpera's Cancer Research
June 9, 2015
GenSpera's CEO Craig A. Dionne Interviewed on Sirius Radio
June 3, 2015
GenSpera's CEO Craig A. Dionne to Present H.C. Wainwright & Co.'s Panel Discussion during ASCO 2015
May 20, 2015
GenSpera Expands Phase II Glioblastoma Trial of Mipsagargin
May 13, 2015
GenSpera Provides Corporate Update
May 11, 2015
GenSpera Enters National Phase with Patent Application for Injectable Prodrug Formulations
May 6, 2015
GenSpera Granted New Patent for Prodrugs Activated by Prostate Specific Antigen
April 28, 2015
GenSpera Launches National Investor Relations Program
March 30, 2015
OTC Markets Group Welcomes Newly Verified OTCQB Companies – March 25
March 25, 2015
GenSpera Presents at BIO Asia International Conference
March 17, 2015